海曲泊帕治疗慢性原发免疫性血小板减少症的临床疗效和安全性观察

Efficacy and safety of hetrombopag in the treatment of chronic primary immune thrombocytopenia

目的:探究海曲泊帕治疗慢性原发免疫性血小板减少症(primary immune thrombocytopenia,ITP)的临床疗效和安全性。方法:选取2021年6月—2022年12月我院血液内科收治的25例慢性ITP患者纳入本研究,观察海曲泊帕治疗慢性ITP的有效率、起效时间、达到峰值所需时间、治疗前后血小板水平以及不良反应。结果:本研究中海曲泊帕治疗慢性ITP患者的疗效显著,总有效率达80%;中位起效时间为12(5~23)d;达到血小板峰值所需的中位时间为4.5(1.5~6.5)周。25例慢性ITP患者治疗前血小板平均水平为(13.71±5.31)×10^(9)/L,治疗后显著上升至(83.35±6.28)×10^(9)/L,差异有统计学意义(P<0.05)。25例慢性ITP患者治疗前出血评分为0、1、2级者分别为6、15、4例,治疗后分别为17、5、3例。治疗后出血评分显著降低,与治疗前比较差异有统计学意义(P<0.05)。治疗期间出现肝功能异常患者3例,予以口服保肝药物治疗后肝功能均恢复正常;出现腹泻患者1例,予以口服止泻药物后好转;无一例患者因不良反应停药。结论:海曲泊帕治疗慢性ITP患者的疗效显著,安全性良好,可作为慢性ITP患者的治疗方案之一。

Objective:To investigate the clinical efficacy and safety of hetrombopag in the treatment of chronic primary immune thrombocytopenia(ITP).Methods:A total of 25 patients with chronic ITP were enrolled from June 2021 to December 2022.The effective rate,onset time,peak time,platelet level before and after treatment and adverse events of hetrombopag in the treatment of chronic ITP were observed.Results:The results of this study showed that hetrombopag was effective in the treatment of patients with chronic ITP,and the total effective rate was 80%,the median effective time was 12(5-23)days,and the median time to reach platelet peak was 4.5(1.5-6.5)weeks.The average platelet level of 25 patients with chronic ITP before treatment was(13.71±5.31)×10^(9)/L.It was significantly increased to(83.35±6.28)×10^(9)/L after treatment(P<0.05).Before treatment,the bleeding scores of grade 0,1 and 2 in 25 patients were 6 cases,15 cases and 4 cases,respectively,and after treatment there were 17 cases,5 cases and 3 cases,respectively.The bleeding score decreased significantly after treatment(P<0.05).During the treatment,there were 3 cases of abnormal liver function,which returned to normal after oral treatment with hepatoprotective drugs,and 1 case of diarrhea improved after oral antidiarrheal drugs,and no patient stopped taking drugs because of adverse events.Conclusion:Hetrombopag is effective and safe in the treatment of chronic ITP patients,and can be used as one of the treatment options for chronic ITP patients.